Search research articles
Contact Us
Filters
Showing results (31-40 of 93) with videos related to
Page
of 10
Sort By:
European Journal of Haematology
|
November 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos, et al.
Cancer
|
April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens
Giulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
Cancer
|
October 26, 2012
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study
Maria Teresa Petrucci, Anna Levi, Sara Bringhen, et al.
Haematologica
|
July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel
Valerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
International Journal of Laboratory Hematology
|
August 27, 2021
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
Yan-Ting Chen, Erik T Valent, Erik H van Beers, et al.
European Journal of Haematology
|
January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Paul Richardson, Meral Beksaç, Albert Oriol, et al.
American Journal of Hematology
|
April 14, 2020
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
Paolo Milani, Francesca Fazio, Marco Basset, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Blood Cancer Journal
|
January 4, 2023
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Hira Mian, Arleigh McCurdy, Smith Giri, et al.
Clinical Lymphoma & Myeloma
|
May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
Antonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 93) with videos related to
Sort By:
Page
of 10
European Journal of Haematology
|
November 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos, et al.
Cancer
|
April 22, 2011
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens
Giulia Benevolo, Alessandra Larocca, Massimo Gentile, et al.
Cancer
|
October 26, 2012
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study
Maria Teresa Petrucci, Anna Levi, Sara Bringhen, et al.
Haematologica
|
July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel
Valerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
International Journal of Laboratory Hematology
|
August 27, 2021
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
Yan-Ting Chen, Erik T Valent, Erik H van Beers, et al.
European Journal of Haematology
|
January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
Paul Richardson, Meral Beksaç, Albert Oriol, et al.
American Journal of Hematology
|
April 14, 2020
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
Paolo Milani, Francesca Fazio, Marco Basset, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Blood Cancer Journal
|
January 4, 2023
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Hira Mian, Arleigh McCurdy, Smith Giri, et al.
Clinical Lymphoma & Myeloma
|
May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
Antonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Page
of 10